Central Retinal Vein Occlusion 

  • Author: Lakshmana M Kooragayala, MD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Jan 5, 2011
 

Background

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder. Clinically, CRVO presents with variable visual loss; the fundus may show retinal hemorrhages, dilated tortuous retinal veins, cotton-wool spots, macular edema, and optic disc edema. Note the images below.

Recent onset central retinal vein occlusion, showiRecent onset central retinal vein occlusion, showing extensive hemorrhages in the posterior pole and giving the "blood and thunder appearance." Peripheral fundus view of the same patient as in tPeripheral fundus view of the same patient as in the previous image, showing hemorrhages extending all over the fundus. Fluorescein angiograph of same patient as in previFluorescein angiograph of same patient as in previous images, showing hypofluorescence due to blockage from hemorrhages in the retina. It is not useful to perform a fluorescein angiogram in acute stages of the disease. Fundus picture of the same patient as in previous Fundus picture of the same patient as in previous images, showing resolving neovascularization of the disc and panretinal photocoagulation scars. Fluorescein angiogram of the same patient as in thFluorescein angiogram of the same patient as in the previous images, taken more than 1 year later, showing persistent cystoid macular edema with good laser spots.

In view of the devastating complications associated with the severe form of CRVO, a number of classifications were described in the literature. All of these classifications take into account the area of retinal capillary nonperfusion and the development of neovascular complications.[1, 2, 3, 4, 5]

Broadly, CRVO can be divided into 2 clinical types, ischemic and nonischemic. In addition, a number of patients may have an intermediate in presentation with variable clinical course. On initial presentation, it may be difficult to classify a given patient into either category, since CRVO may change with time.

A number of clinical and ancillary investigative factors are taken into account for classifying CRVO, including vision at presentation, presence or absence of relative afferent pupillary defect, extent of retinal hemorrhages, cotton-wool spots, extent of retinal perfusion by fluorescein angiography, and electroretinographic changes.

Nonischemic CRVO is the milder form of the disease. It may present with good vision, few retinal hemorrhages and cotton-wool spots, no relative afferent pupillary defect, and good perfusion to the retina. Nonischemic CRVO may resolve fully with good visual outcome or may progress to the ischemic type. Note the images below.

Patient with nonischemic central retinal vein occlPatient with nonischemic central retinal vein occlusion presented with dilated, tortuous veins and superficial hemorrhages. Fundus picture of the same patient as in previous Fundus picture of the same patient as in previous image, showing resolved hemorrhages and pigmentary changes in the macula several months later.

Ischemic CRVO is the severe form of the disease. CRVO may present initially as the ischemic type, or it may progress from nonischemic. Usually, ischemic CRVO presents with severe visual loss, extensive retinal hemorrhages and cotton-wool spots, presence of relative afferent pupillary defect, poor perfusion to retina, and presence of severe electroretinographic changes. In addition, patients may end up with neovascular glaucoma and a painful blind eye.

Next

Pathophysiology

The exact pathogenesis of the thrombotic occlusion of the central retinal vein is not known. Various local and systemic factors play a role in the pathological closure of the central retinal vein.[3, 6, 7]

The central retinal artery and vein share a common adventitial sheath as they exit the optic nerve head and pass through a narrow opening in the lamina cribrosa. Because of this narrow entry in the lamina cribrosa, the vessels are in a tight compartment with limited space for displacement. This anatomical position predisposes to thrombus formation in the central retinal vein by various factors, including slowing of the blood stream, changes in the vessel wall, and changes in the blood.

Arteriosclerotic changes in the central retinal artery transform the artery into a rigid structure and impinge upon the pliable central retinal vein, causing hemodynamic disturbances, endothelial damage, and thrombus formation. This mechanism explains the fact that there will be an associated arterial disease with CRVO. However, this association has not been proven consistently, and various authors disagree on this fact.

Thrombotic occlusion of the central retinal vein can occur as a result of various pathologic insults, including compression of the vein (mechanical pressure due to structural changes in lamina cribrosa, eg, glaucomatous cupping, inflammatory swelling in optic nerve, orbital disorders); hemodynamic disturbances (associated with hyperdynamic or sluggish circulation); vessel wall changes (eg, vasculitis); and changes in the blood (eg, deficiency of thrombolytic factors, increase in clotting factors).

Occlusion of the central retinal vein leads to the backup of the blood in the retinal venous system and increased resistance to venous blood flow. This increased resistance causes stagnation of the blood and ischemic damage to the retina. It has been postulated that ischemic damage to the retina stimulates increased production of vascular endothelial growth factor (VEGF) in the vitreous cavity. Increased levels of VEGF stimulate neovascularization of the posterior and anterior segment (responsible for secondary complications due to CRVO). Also, it has been shown that VEGF causes capillary leakage leading to macular edema (which is the leading cause of visual loss in both ischemic CRVO and nonischemic CRVO).

The prognosis of CRVO depends upon the reestablishment of patency of the venous system by recanalization, dissolution of clot, or formation of optociliary shunt vessels.

Previous
Next

Epidemiology

Frequency

United States

CRVO and branch retinal vein occlusion constitute the second most common retinal vascular disorder. The nonischemic type is more common than the ischemic type.

In a recent publication, the Beaver Dam Eye Study Group reported the 15-year cumulative incidence of CRVO to be 0.5%.[8]

International

A large population-based study in Israel reported a 4-year incidence of retinal vein occlusion of 2.14 cases per 1000 of general population older than 40 years and 5.36 cases per 1000 of general population older than 64 years.

In Australia, the prevalence of vein occlusion ranges from 0.7% in patients aged 49-60 years to 4.6% in patients older than 80 years.[9]

Mortality/Morbidity

CRVO is not associated directly with increased mortality.

Nonischemic CRVO may resolve completely without any complications in about 10% of cases. In about 50% of patients, vision may be 20/200 or worse. One third of patients may progress to the ischemic type, commonly in the first 6-12 months after presentation.

In more than 90% of patients with ischemic CRVO, final visual acuity may be 20/200 or worse. Anterior segment neovascularization with associated neovascular glaucoma develops in more than 60% of cases. This can happen within a few weeks and up to 1-2 years afterward.

It has been reported that the fellow eye may develop retinal vein occlusion in about 7% of cases within 2 years. In another report, the 4-year risk of developing second venous occlusion is 2.5% in the same eye and 11.9% in the fellow eye. Neovascular glaucoma may result in a painful blind eye.

Race

CRVO does not have any particular racial preference.

Sex

CRVO occurs slightly more frequently in males than in females.

Age

More than 90% of CRVO occurs in patients older than 50 years, but it has been reported in all age groups.

Previous
 
 
Contributor Information and Disclosures
Author

Lakshmana M Kooragayala, MD  Vitreo-retinal Surgeon, Marietta Eye Clinic

Lakshmana M Kooragayala, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, and Medical Association of Georgia

Disclosure: Nothing to disclose.

Specialty Editor Board

V Al Pakalnis, MD, PhD  Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center

V Al Pakalnis, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and South Carolina Medical Association

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD  Associate Professor of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Steve Charles, MD  Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine; Adjunct Professor of Ophthalmology, Columbia College of Physicians and Surgeons; Clinical Professor Ophthalmology, Chinese University of Hong Kong

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Club Jules Gonin, Macula Society, and Retina Society

Disclosure: Alcon Laboratories Consulting fee Consulting; OptiMedica Ownership interest Other; Topcon Medical Lasers Consulting fee Consulting

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the assistance of Ryan I Huffman, MD, with the literature review and referencing for this article.

References
  1. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. [published erratum appears in Arch Ophthalmol 1997 Oct;115(10):1275]. Arch Ophthalmol. Apr 1997;115(4):486-91. [Medline].

  2. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology. May 1983;90(5):458-74. [Medline].

  3. Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. Sep 1994;42(3):109-32. [Medline].

  4. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. Apr 15 1994;117(4):429-41. [Medline].

  5. Williamson TH. Central retinal vein occlusion: what's the story?. Br J Ophthalmol. Aug 1997;81(8):698-704. [Medline].

  6. David R, Zangwill L, Badarna M, et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica. 1988;197(2):69-74. [Medline].

  7. Ota M, Tsujikawa A, Kita M, et al. Integrity of foveal photoreceptor layer in central retinal vein occlusion. Retina. Nov-Dec 2008;28(10):1502-8. [Medline].

  8. Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. Apr 2008;126(4):513-8. [Medline].

  9. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. Oct 1996;114(10):1243-7. [Medline].

  10. Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Ophthalmol. Aug 1993;111(8):1087-95. [Medline].

  11. Glacet-Bernard A, les Jardins GL, Lasry S, Coscas G, Soubrane G, Souied E, et al. Obstructive sleep apnea among patients with retinal vein occlusion. Arch Ophthalmol. Dec 2010;128(12):1533-8. [Medline].

  12. Baxter GM, Williamson TH. Color Doppler flow imaging in central retinal vein occlusion: a new diagnostic technique?. Radiology. Jun 1993;187(3):847-50. [Medline].

  13. Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol. Mar 2008;116(2):147-52. [Medline].

  14. Gupta B, Grewal J, Adewoyin T, et al. Diurnal variation of macular oedema in CRVO: prospective study. Graefes Arch Clin Exp Ophthalmol. Dec 4 2008;[Medline].

  15. Breton ME, Quinn GE, Keene SS, et al. Electroretinogram parameters at presentation as predictors of rubeosis in central retinal vein occlusion patients. Ophthalmology. Sep 1989;96(9):1343-52. [Medline].

  16. Sato E, Yamamoto S, Ogata K, et al. Changes of electroretinogram without improvement of retinal circulation after radial optic neurotomy for central retinal vein occlusion. ERG changes after RON for CRVO. Doc Ophthalmol. Mar 2008;116(2):153-8. [Medline].

  17. Green WR, Chan CC, Hutchins GM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina. 1981;1:27-55.

  18. Bashshur ZF, Ma'luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. Aug 2004;122(8):1137-40. [Medline].

  19. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina. Oct-Nov 2005;25(7):846-50. [Medline].

  20. Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. Aug 2004;122(8):1131-6. [Medline].

  21. Patel PJ, Zaheer I, Karia N. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye. Jan 2008;22(1):60-4. [Medline].

  22. Ramchandran RS, Fekrat S, Stinnett SS, et al. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am J Ophthalmol. Aug 2008;146(2):285-291. [Medline].

  23. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. Sep 2009;127(9):1101-14. [Medline]. [Full Text].

  24. Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. Feb 2008;28(1):59-61. [Medline].

  25. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol. Dec 2007;144(6):864-71. [Medline].

  26. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. Apr 2008;92(4):518-22. [Medline].

  27. Spaide RF, Chang LK, Klancnik JM, et al. Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion. Am J Ophthalmol. Oct 17 2008;[Medline].

  28. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. Jun 2010;117(6):1134-1146.e3. [Medline].

  29. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. Jun 2010;117(6):1124-1133.e1. [Medline].

  30. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol. Sep 2010;150(3):310-4. [Medline].

  31. Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. Oct 1995;102(10):1434-44. [Medline].

  32. Central Vein Occlusion Study Group. Central vein occlusion study of photocoagulation therapy. Baseline findings. Online J Curr Clin Trials. Oct 14 1993;Doc No 95:[Medline].

  33. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. Oct 1995;102(10):1425-33. [Medline].

  34. Browning DJ, Rotberg MH. Vitreous Hemorrhage complicating laser-induced chorioretinal anastomosis for central retinal vein occlusion. Am J Ophthalmol. Oct 1996;122(4):588-9. [Medline].

  35. Eccarius SG, Moran MJ, Slingsby JG. Choroidal neovascular membrane after laser-induced chorioretinal anastomosis. Am J Ophthalmol. Oct 1996;122(4):590-1. [Medline].

  36. Luttrull JK. Epiretinal membrane and traction retinal detachment complicating laser- induced chorioretinal venous anastomosis. Am J Ophthalmol. May 1997;123(5):698-9. [Medline].

  37. McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol. Apr 1995;113(4):456-62. [Medline].

  38. Mirshahi A, Roohipoor R, Lashay A, et al. Surgical induction of chorioretinal venous anastomosis in ischaemic central retinal vein occlusion: a non-randomised controlled clinical trial. Br J Ophthalmol. Jan 2005;89(1):64-9. [Medline].

  39. Beck AP, Ryan EA, Lou PL, et al. Controversies regarding radial optic neurotomy for central retinal vein occlusion. Int Ophthalmol Clin. Fall 2005;45(4):153-61. [Medline].

  40. Binder S, Aggermann T, Brunner S. Long-term effects of radial optic neurotomy for central retinal vein occlusion consecutive interventional case series. Graefes Arch Clin Exp Ophthalmol. Oct 2007;245(10):1447-52. [Medline].

  41. Friberg TR, Smolinski P, Hill S, et al. Biomechanical assessment of radial optic neurotomy. Ophthalmology. Jan 2008;115(1):174-80. [Medline].

  42. Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina. 2001;21(5):408-15. [Medline].

  43. Weizer JS, Stinnett SS, Fekrat S. Radial optic neurotomy as treatment for central retinal vein occlusion. Am J Ophthalmol. Nov 2003;136(5):814-9. [Medline].

  44. Arevalo JF, Garcia RA, Wu L, et al. Radial optic neurotomy for central retinal vein occlusion: results of the Pan-American Collaborative Retina Study Group (PACORES). Retina. Oct 2008;28(8):1044-52. [Medline].

  45. Leizaola-Fernandez C, Suarez-Tata L, Quiroz-Mercado H, et al. Vitrectomy with complete posterior hyaloid removal for ischemic central retinal vein occlusion: series of cases. BMC Ophthalmol. May 20 2005;5:10. [Medline].

  46. Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol. Aug 2005;140(2):200-6. [Medline].

Previous
Next
 
Recent onset central retinal vein occlusion, showing extensive hemorrhages in the posterior pole and giving the "blood and thunder appearance."
Peripheral fundus view of the same patient as in the previous image, showing hemorrhages extending all over the fundus.
Fluorescein angiograph of same patient as in previous images, showing hypofluorescence due to blockage from hemorrhages in the retina. It is not useful to perform a fluorescein angiogram in acute stages of the disease.
Fundus picture of the same patient as in previous images, showing resolving neovascularization of the disc and panretinal photocoagulation scars.
Fluorescein angiogram of the same patient as in the previous images, taken more than 1 year later, showing persistent cystoid macular edema with good laser spots.
Patient with nonischemic central retinal vein occlusion presented with dilated, tortuous veins and superficial hemorrhages.
Fundus picture of the same patient as in previous image, showing resolved hemorrhages and pigmentary changes in the macula several months later.
Central retinal vein occlusion showing significant disc edema with dilated tortuous veins and scattered retinal hemorrhages.
Fluorescein angiogram of the same patient in as in previous image, showing leakage from disc, staining of retinal veins.
Fundus of a patient with nonischemic central retinal vein occlusion, showing few scattered peripheral fundus hemorrhages.
Scattered retinal hemorrhages in a patient with central retinal vein occlusion.
Fluorescein angiogram of a patient with nonischemic central retinal vein occlusion, showing staining of dilated tortuous veins with leakage into macula in a cystoid pattern.
Fluorescein angiogram of the same patient as in previous image, showing perifoveal capillary leakage in a cystoid pattern in late phases of angiogram.
Late phase of fluorescein angiograph of the same patient as in previous image, showing cystoid pattern of leakage from perifoveal dilated leaking capillary network.
Arteriovenous phase of fluorescein angiograph showing perifoveal capillary leakage in a patient with nonischemic central retinal vein occlusion.
Fundus picture of a well-compensated, old central retinal vein occlusion showing optociliary shunt vessels.
Red-free photo of the same patient as in the previous image, showing prominent optociliary shunt vessels.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.